BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 28030834)

  • 21. A novel alkylating deacetylase inhibitor molecule EDO-S101 in combination with cytarabine synergistically enhances apoptosis of acute myeloid leukemia cells.
    Jin J; Mao S; Li F; Li X; Huang X; Yu M; Guo W; Jin J
    Med Oncol; 2019 Aug; 36(9):77. PubMed ID: 31372848
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of CHK1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells.
    Zhao J; Niu X; Li X; Edwards H; Wang G; Wang Y; Taub JW; Lin H; Ge Y
    Oncotarget; 2016 Jun; 7(23):34785-99. PubMed ID: 27166183
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells.
    Fiskus W; Sharma S; Qi J; Valenta JA; Schaub LJ; Shah B; Peth K; Portier BP; Rodriguez M; Devaraj SG; Zhan M; Sheng J; Iyer SP; Bradner JE; Bhalla KN
    Mol Cancer Ther; 2014 May; 13(5):1142-54. PubMed ID: 24435446
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tunneling nanotube (TNT) formation is downregulated by cytarabine and NF-κB inhibition in acute myeloid leukemia (AML).
    Omsland M; Bruserud Ø; Gjertsen BT; Andresen V
    Oncotarget; 2017 Jan; 8(5):7946-7963. PubMed ID: 27974700
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL.
    Stubbs MC; Kim W; Bariteau M; Davis T; Vempati S; Minehart J; Witkin M; Qi J; Krivtsov AV; Bradner JE; Kung AL; Armstrong SA
    Clin Cancer Res; 2015 May; 21(10):2348-58. PubMed ID: 25688158
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells.
    Ha K; Fiskus W; Choi DS; Bhaskara S; Cerchietti L; Devaraj SG; Shah B; Sharma S; Chang JC; Melnick AM; Hiebert S; Bhalla KN
    Oncotarget; 2014 Jul; 5(14):5637-50. PubMed ID: 25026298
    [TBL] [Abstract][Full Text] [Related]  

  • 27. How to Distinguish Between the Activity of HDAC1-3 and HDAC6 with Western Blot.
    Beyer M; Kiweler N; Mahboobi S; Krämer OH
    Methods Mol Biol; 2017; 1510():355-364. PubMed ID: 27761834
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting AML1/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells.
    Liu S; Klisovic RB; Vukosavljevic T; Yu J; Paschka P; Huynh L; Pang J; Neviani P; Liu Z; Blum W; Chan KK; Perrotti D; Marcucci G
    J Pharmacol Exp Ther; 2007 Jun; 321(3):953-60. PubMed ID: 17389244
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Panobinostat for the treatment of acute myelogenous leukemia.
    Morabito F; Voso MT; Hohaus S; Gentile M; Vigna E; Recchia AG; Iovino L; Benedetti E; Lo-Coco F; Galimberti S
    Expert Opin Investig Drugs; 2016 Sep; 25(9):1117-31. PubMed ID: 27485472
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synergistic loss of prostate cancer cell viability by coinhibition of HDAC and PARP.
    Chao OS; Goodman OB
    Mol Cancer Res; 2014 Dec; 12(12):1755-66. PubMed ID: 25127709
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Protection of acute myeloid leukaemia cells from apoptosis induced by front-line chemotherapeutics is mediated by haem oxygenase-1.
    Heasman SA; Zaitseva L; Bowles KM; Rushworth SA; Macewan DJ
    Oncotarget; 2011 Sep; 2(9):658-68. PubMed ID: 21911919
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pleiotropic effects of spongean alkaloids on mechanisms of cell death, cell cycle progression and DNA damage response (DDR) of acute myeloid leukemia (AML) cells.
    Stuhldreier F; Kassel S; Schumacher L; Wesselborg S; Proksch P; Fritz G
    Cancer Lett; 2015 May; 361(1):39-48. PubMed ID: 25697484
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enhanced Histone Deacetylase Activity in Malignant Melanoma Provokes RAD51 and FANCD2-Triggered Drug Resistance.
    Krumm A; Barckhausen C; Kücük P; Tomaszowski KH; Loquai C; Fahrer J; Krämer OH; Kaina B; Roos WP
    Cancer Res; 2016 May; 76(10):3067-77. PubMed ID: 26980768
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of Class I Histone Deacetylases 1 and 2 Promotes Urothelial Carcinoma Cell Death by Various Mechanisms.
    Pinkerneil M; Hoffmann MJ; Deenen R; Köhrer K; Arent T; Schulz WA; Niegisch G
    Mol Cancer Ther; 2016 Feb; 15(2):299-312. PubMed ID: 26772204
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The histone deacetylase inhibitor valproic acid alters sensitivity towards all trans retinoic acid in acute myeloblastic leukemia cells.
    Trus MR; Yang L; Suarez Saiz F; Bordeleau L; Jurisica I; Minden MD
    Leukemia; 2005 Jul; 19(7):1161-8. PubMed ID: 15902297
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sensitivity and gene expression profile of fresh human acute myeloid leukemia cells exposed ex vivo to AS602868.
    Jordheim LP; Plesa A; Dreano M; Cros-Perrial E; Keime C; Herveau S; Demangel D; Vendrell JA; Dumontet C
    Cancer Chemother Pharmacol; 2011 Jul; 68(1):97-105. PubMed ID: 20844879
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Low expression of GFI-1 Gene is associated with Panobinostat-resistance in acute myeloid leukemia through influencing the level of HO-1.
    Cheng B; Tang S; Zhe N; Ma D; Yu K; Wei D; Zhou Z; Lu T; Wang J; Fang Q
    Biomed Pharmacother; 2018 Apr; 100():509-520. PubMed ID: 29494986
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular and biologic characterization and drug sensitivity of pan-histone deacetylase inhibitor-resistant acute myeloid leukemia cells.
    Fiskus W; Rao R; Fernandez P; Herger B; Yang Y; Chen J; Kolhe R; Mandawat A; Wang Y; Joshi R; Eaton K; Lee P; Atadja P; Peiper S; Bhalla K
    Blood; 2008 Oct; 112(7):2896-905. PubMed ID: 18660379
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of class IIa histone deacetylase activity by gallic acid, sulforaphane, TMP269, and panobinostat.
    Choi SY; Kee HJ; Jin L; Ryu Y; Sun S; Kim GR; Jeong MH
    Biomed Pharmacother; 2018 May; 101():145-154. PubMed ID: 29482060
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Class I Histone Deacetylase HDAC1 and WRN RECQ Helicase Contribute Additively to Protect Replication Forks upon Hydroxyurea-induced Arrest.
    Kehrli K; Phelps M; Lazarchuk P; Chen E; Monnat R; Sidorova JM
    J Biol Chem; 2016 Nov; 291(47):24487-24503. PubMed ID: 27672210
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.